Dobromir Dimitrov1, Marie-Claude Boily2, Benoît R Mâsse3, Elizabeth R Brown1. 1. Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, USA. 2. Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College London, London, UK. 3. CHU Sainte-Justine Research Centre, University of Montreal, Montreal, Quebec, Canada.
Abstract
BACKGROUND: The first antiretroviral drug (Truvada) to be used as a pre-exposure prophylaxis (PrEP) in preventing HIV transmission is about to be approved. Behavioral studies suggest that a portion of users may share anti-retroviral drugs with sex partners, family, or friends. Pill sharing will decrease PrEP efficacy and adherence level, and potentially create an environment favorable for the development of drug resistance. We aim to evaluate the potential impact of pill sharing on the PrEP effectiveness and on the rates of drug-resistance development in heterosexual populations. METHODS: A transmission dynamic model was used to assess the population-level impact of oral PrEP. The fractions of new HIV infections prevented (CPF), drug resistance prevalence and the proportion of new infections in which drug-resistant HIV is transmitted (TDR) are evaluated over fixed time periods. The influence of different factors on CPF and TDR is studied through simulations, using epidemic parameters representative of the countries in Sub-Saharan Africa. RESULTS: Without pill sharing, a 70% efficacious PrEP used consistently by 60% of uninfected individuals prevents 52.8% (95% CI 49.4%-56.4%) of all new HIV infections over ten years with drug-resistant HIV transmitted in 2.2% of the new infections. Absolute CPF may vary by 9% if up to 20% of the users share PrEP while the level of TDR and total resistance prevalence may increase by up to 6-fold due to pill sharing in some intervention scenarios. CONCLUSION: Pill sharing may increase the PrEP coverage level achieved in the population but it also affects the PrEP efficacy for the users who do not follow the prescribed schedule. More importantly, it creates a pool of untracked users who remain unreached by the effort to avoid sub-optimal PrEP usage by infected people. This increases substantially the potential risk of drug resistance in the population.
BACKGROUND: The first antiretroviral drug (Truvada) to be used as a pre-exposure prophylaxis (PrEP) in preventing HIV transmission is about to be approved. Behavioral studies suggest that a portion of users may share anti-retroviral drugs with sex partners, family, or friends. Pill sharing will decrease PrEP efficacy and adherence level, and potentially create an environment favorable for the development of drug resistance. We aim to evaluate the potential impact of pill sharing on the PrEP effectiveness and on the rates of drug-resistance development in heterosexual populations. METHODS: A transmission dynamic model was used to assess the population-level impact of oral PrEP. The fractions of new HIV infections prevented (CPF), drug resistance prevalence and the proportion of new infections in which drug-resistant HIV is transmitted (TDR) are evaluated over fixed time periods. The influence of different factors on CPF and TDR is studied through simulations, using epidemic parameters representative of the countries in Sub-Saharan Africa. RESULTS: Without pill sharing, a 70% efficacious PrEP used consistently by 60% of uninfected individuals prevents 52.8% (95% CI 49.4%-56.4%) of all new HIV infections over ten years with drug-resistant HIV transmitted in 2.2% of the new infections. Absolute CPF may vary by 9% if up to 20% of the users share PrEP while the level of TDR and total resistance prevalence may increase by up to 6-fold due to pill sharing in some intervention scenarios. CONCLUSION: Pill sharing may increase the PrEP coverage level achieved in the population but it also affects the PrEP efficacy for the users who do not follow the prescribed schedule. More importantly, it creates a pool of untracked users who remain unreached by the effort to avoid sub-optimal PrEP usage by infected people. This increases substantially the potential risk of drug resistance in the population.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Romulus Breban; Ian McGowan; Chad Topaz; Elissa J Schwartz; Peter Anton; Sally Blower Journal: Math Biosci Eng Date: 2006-07 Impact factor: 2.080
Authors: Jan Weber; Bikram Chakraborty; Jitka Weberova; Michael D Miller; Miguel E Quiñones-Mateu Journal: J Clin Microbiol Date: 2005-03 Impact factor: 5.948
Authors: Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman Journal: J Virol Date: 2008-03-19 Impact factor: 5.103
Authors: Frits van Griensven; Jan Willem de Lind van Wijngaarden; Stefan Baral; Andrew Grulich Journal: Curr Opin HIV AIDS Date: 2009-07 Impact factor: 4.283
Authors: Stefan Baral; Gift Trapence; Felistus Motimedi; Eric Umar; Scholastika Iipinge; Friedel Dausab; Chris Beyrer Journal: PLoS One Date: 2009-03-26 Impact factor: 3.240
Authors: Priya Srinivasan; John A Moss; Manjula Gunawardana; Scott A Churchman; Flora Yang; Chuong T Dinh; James M Mitchell; Jining Zhang; Rob Fanter; Christine S Miller; Irina Butkyavichene; Janet M McNicholl; Thomas J Smith; Marc M Baum; James M Smith Journal: PLoS One Date: 2016-06-08 Impact factor: 3.240
Authors: Dobromir T Dimitrov; Marie-Claude Boily; Timothy B Hallett; Jan Albert; Charles Boucher; John W Mellors; Deenan Pillay; David A M C van de Vijver Journal: PLoS One Date: 2016-07-08 Impact factor: 3.240